

Table S1. Criteria for generating the study cohort.

Filter 1	Formal exclusion criteria
	• ASA low dose (<300mg/d)/anticoagulation prophylaxis • ASA dosage unclear • No exposure to study medication during pregnancy course • Exposure to study medication in 1st trimester only • Unspecified exposure to study medication in pregnancy not assignable with certainty to the 2nd/3rd trimester • Only rudimentary information not sufficient for assessment • Fetal or neonatal death caused by severe maternal illness or death • Duplicate
Filter 2	Content-related exclusion criteria
	• Drug over dose/suicide attempt • Teratogenic or fetotoxic co-medication of significant relevance • Other co-medication of significant relevance considered as reason for reporting • Relevant maternal infectious diseases • Severe or complex maternal illness and/or multiple concomitant diseases • Multiple malformations in the fetus/child, (supposed) genetic disease • Severe/complex heart defect in the fetus/child • PDA in preterm-born infants if no other endpoints were present • Duplicate (if it was recognised after filter 1)

All ADR reports identified from VigilanceCentral, EudraVigilance, and VigiBase were individually checked. These criteria were applied in filter 1 and filter 2 to obtain the final study cohort.